Category: Parkinsonism, Atypical: PSP, CBD
Objective: To investigate the pattern of comorbidities and comedications in PSP patients compared to age-matched controls.
Background: Although progressive supranuclear palsy (PSP) is usually diagnosed in elderly, little is known about comorbidities and comedications in these patients.
Method: Cross-sectional data of PSP and control patients without neurodegenerative diseases were collected from German multicenter cohorts (DescribePSP, ProPSP, DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®.
Results: In total, 335 PSP and 275 age- and sex-matched control patients were included in this analysis. Although the number of comorbidities did not differ between the groups (PSP, 3.6 ± 2.4; controls, 3.4 ± 2.4; P = 0.263), the prevalence of neurological, psychiatric and cardiovascular diseases at first level of ICD-10 was higher in PSP. Diabetes mellitus, polyneuropathies and cerebrovascular diseases were more frequent in PSP at second level of ICD-10. PSP patients received more drugs (PSP, 5.2 ± 3.0; controls, 2.8 ± 2.4; P < 0.001), resulting in a higher percentage of patients with polypharmacy (PSP, 54.0%; controls, 20.4%; P < 0.001). Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.
Conclusion: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.
To cite this abstract in AMA style:
S. Greten, F. Wegner, O. Krause, J. Heck, GU. Höglinger, M. Klietz. The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/the-comorbidity-and-comedication-profiles-of-patients-with-progressive-supranuclear-palsy-in-two-german-multicenter-cohorts-a-systematic-cross-sectional-analysis/. Accessed December 9, 2024.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-comorbidity-and-comedication-profiles-of-patients-with-progressive-supranuclear-palsy-in-two-german-multicenter-cohorts-a-systematic-cross-sectional-analysis/